NovoBioPharma, a partnership of experts collaborating with life science organizations to provide medical, scientific, regulatory, business and financial advisory services, has launched. The global business has four principals who have partnered to help life science companies and institutions advance drug, diagnostic and device candidates by leveraging opportunities from conception through clinical development and regulatory approval.

NovoBioPharma offers services in capital sourcing and management, business development, intellectual property, quality control, manufacturing, study design and protocol development. The four principals are Bernie Rudnick, M.B.A., chief business officer; Ira Wallace, M.D., M.B.A., chief development officer; Shahin Gharakhanian M.D., head of pharmaceutical medicine; and Andrew D. Luber, chief scientific officer.

Rudnick is founder and managing partner of CapGenic Advisors and a founding member of several angel investing groups; he has led capital formation of $530 million in the past 10 years and $3 billion during the last 15 years. Rudnick founded, managed and advised companies in the life sciences, including diagnostic, therapeutic and clinical software environments. 

Wallace has been involved in pharmaceutical, biotech and medical device companies as a chief executive officer, founder, board member and consultant. Wallace has experience in technology transfer and intellectual property strategies and is a founding member and partner in several angel investment groups.

Gharakhanian is an infectious diseases and internal medicine trained physician with 20 years of experience in the pharmaceutical industry and clinical practice. His was vice president in the medicines development group/global R&D at Vertex Pharmaceuticals. Gharakhanian has handled projects for 12 different pharmaceutical companies, 10 different brands and four drug launches in Asia, Canada, the E.U. and the U.S.

Luber is an infectious diseases trained clinical pharmacist/pharmacologist with 18 years of experience working with the pharmaceutical industry as an investigator, opinion leader, speakers’ bureau, steering committee and advisory board member. He has served as a clinical consultant to large and early stage pharmaceutical companies. Luber has been an investigator in more than 70 clinical trials including four phase Ia first-in-human studies and specializes in early stage drug development.